Large Inflow of Money Witnessed in United Therapeutics Corporation

United Therapeutics Corporation (NASDAQ:UTHR) : Investors lapped up stocks on upticks to the tune of $1.02 million in the Wednesdays trading session. The trading value on downticks was comparatively at $0.22 million and the uptick to downtick ratio of 4.55 indicates continuous buying by the bulls. The net money flow into the stock was $0.79 million. Upticks saw transactions worth $0.01 clearly indicating buying by large investors. The total money flow for block trades stood at $0.01 million, which is a positive for the stock in the long-term. United Therapeutics Corporation (NASDAQ:UTHR) fell $0.07 during the day at $101.65, a drop of -0.07% over the previous days close. However, for the week, the stock is -0.45%, compared to the previous week.


In an insider trading activity, Rothblatt Martine A, director officer (Chairman & Co-CEO) of United Therapeutics Corp, unloaded 1,308 shares at an average price of $105 on June 16, 2016. The total amount of the transaction was worth $137,340, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing. Currently the company Insiders own 7.5% of United Therapeutics Corporation shares according to the proxy statements.

The company shares have dropped -41.18% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $181.03 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $110.91 and the 200 Day Moving Average price is recorded at $122.84. United Therapeutics Corporation (NASDAQ:UTHR): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $102.95 and $100.70 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $104.88. The buying momentum continued till the end and the stock did not give up its gains. It closed at $103.54, notching a gain of 1.79% for the day. The total traded volume was 574,822 . The stock had closed at $101.72 on the previous day.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin, Tyvaso (treprostinil), Adcirca (tadalafil), Remodulin Implantable System, Orenitram Combination Therapy, Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb, for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation, for the treatment of End-stage lung disease; UV-4B, for the treatment of Dengue and influenza, and Glycobiology Antiviral Agents, for the treatment of a spectrum of agents against viral infectious diseases, among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.